Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
An Bras Dermatol ; 89(4): 675-6, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25054764

RESUMO

We report the case of a 81-year-old female patient who had a two-year history of violet-colored erythematous tumors on both legs. Histopathological and immunohistochemical examinations confirmed the diagnosis of primary cutaneous large B-cell lymphoma, leg type. This rare, cutaneous lymphoma affects predominantly elderly females. Clinically, patients present with tumoral lesions on one or both legs (worst prognosis). Diagnosis is based on clinical, histopathological and immunohistochemical findings. The strong expression of BCL2, BCL6, MUM-1 and CD20, and the positivity for Ki67 antigen confirm the diagnosis. R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is the most widely accepted treatment.


Assuntos
Linfoma de Células B/patologia , Neoplasias Cutâneas/patologia , Idoso de 80 Anos ou mais , Evolução Fatal , Feminino , Humanos , Imuno-Histoquímica , Perna (Membro) , Linfoma de Células B/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Resultado do Tratamento
2.
An. bras. dermatol ; 89(4): 675-676, Jul-Aug/2014. graf
Artigo em Inglês | LILACS | ID: lil-715529

RESUMO

We report the case of a 81-year-old female patient who had a two-year history of violet-colored erythematous tumors on both legs. Histopathological and immunohistochemical examinations confirmed the diagnosis of primary cutaneous large B-cell lymphoma, leg type. This rare, cutaneous lymphoma affects predominantly elderly females. Clinically, patients present with tumoral lesions on one or both legs (worst prognosis). Diagnosis is based on clinical, histopathological and immunohistochemical findings. The strong expression of BCL2, BCL6, MUM-1 and CD20, and the positivity for Ki67 antigen confirm the diagnosis. R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is the most widely accepted treatment.


Assuntos
Humanos , Feminino , Idoso de 80 Anos ou mais , Neoplasias Cutâneas/patologia , Linfoma de Células B/patologia , Neoplasias Cutâneas/tratamento farmacológico , Imuno-Histoquímica , Linfoma de Células B/tratamento farmacológico , Resultado do Tratamento , Evolução Fatal , Perna (Membro)
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...